Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Glecaprevir/pibrentasvir Can Reduce HCV Tx Duration

Hepatol Int; ePub 2018 May 29; Abutaleb, et al

Publish date:: June 15, 2018

Glecaprevir/pibrentasvir (GLE/PIB) is a fixed-dose combination therapy approved for hepatitis C virus (HCV) that has expanded reach, reduced cost, and in certain patient populations, reduced HCV treatment duration, according to a recent review. The authors concluded:

GLE/PIB is effective across all genotypes.
GLE/PIB has been shown to be effective in HIV-infected patients, patients with chronic kidney disease (CKD), and Child-Pugh A-compensated cirrhosis.
GLE/PIB is also effective for a shortened duration of 8 weeks in treatment-naïve non-cirrhotic patients.

Citation:

Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. [Published online ahead of print May 29, 2018]. Hepatol Int. doi:10.1007/s12072-018-9873-y.

This Week's Must Reads

HIV, Cancer Treatment, and Prostate Cancer Outcomes Among Elderly Adults,

Low Natural Killer Cell Activity Increases PCa Risk in Veteran Men Undergoing Biopsy,

Prostate CE-TRUS Evaluation with Whole Mount Prostatectomy Correlation,

Testosterone Accumulation in PCa Cells Enhanced by Facilitated Diffusion,

Characterization of GLYATL1 in Prostate Cancer,

Must Reads in Hepatitis

Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al

HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al

HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al

Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al

Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al